Split History
ETFs Holding CALA »    CALA Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Calithera Biosciences is a clinical-stage bio-pharmaceutical company focused on fighting cancer and other life threatening diseases by discovering and developing small molecule drugs that targets cellular metabolism. Co.'s main product candidate, telaglenastat (CB-839), is a selective glutaminase inhibitor that blocks glutamine consumption in tumor cells and demonstrates synergistic antitumor effects with multiple anticancer therapies.Co.'s other product candidate, INCB001158, is an oral inhibitor of arginase, an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells and it is being co-developed with Incyte Corporation, for oncology and hematology indications. According to our CALA split history records, Calithera Biosciences has had 1 split.
CALA split history picture
Calithera Biosciences (CALA) has 1 split in our CALA split history database. The split for CALA took place on July 17, 1996. This was a 2 for 1 split, meaning for each share of CALA owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split.

When a company such as Calithera Biosciences splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the CALA split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Calithera Biosciences shares, starting with a $10,000 purchase of CALA, presented on a split-history-adjusted basis factoring in the complete CALA split history. CALA split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 10/02/2014
End date: 03/02/2021
Start price/share: $9.41
End price/share: $2.88
Dividends collected/share: $0.00
Total return: -69.39%
Average Annual Total Return: -16.84%
Starting investment: $10,000.00
Ending investment: $3,061.38
Years: 6.42
Date Ratio
07/17/19962 for 1
CALA is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CAPR Split History
CASC Split History
CATB Split History
CBIO Split History
CBLI Split History
CBM Split History
CBMX Split History
CBRX Split History
CCM Split History
CDXC Split History

Also explore: CALA shares outstanding history

Guardion Health Sciences, Inc. (GHSI)
China SXT Pharmaceuticals, Inc. (SXTC)
VYNE Therapeutics Inc. (VYNE)
The Sherwin-Williams Company (SHW)
Horizons US Marijuana Index ETF (HMUS)
MicroSectors FANG+ ETNs due January 8, 2038 (FNGS)
MicroSectors FANG+ Index 2X Leveraged ETNs due January 8, 2038 (FNGO)
MicroSectors FANG+ Index 3X Leveraged ETNs due January 8, 2038 (FNGU)
Moleculin Biotech, Inc. (MBRX)
Exela Technologies, Inc. (XELA)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CALA Insider Buying

CALA Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.